This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

YM Bio's Myelofibrosis Drug Is For Real

Updated with additional information.

SAN DIEGO ( TheStreet) -- YM Biosciences (YMI) appears to have a real myelofibrosis drug on its hands.

Highly anticipated results from a mid-stage and multi-center study of YM Bio's myelofibrosis drug CYT387 were released Monday night showing the ballyhooed (and controversial) anemia response maintained.

Of the 68 myelofibrosis patients who were transfusion dependent when the study started, 46% became transfusion independent for a minimum of 12 weeks and maintained hemoglobin levels equal to or above 8 g/dl.

Of the 26 transfusion-dependent patients treated with the 300 mg dose of '387, 62% became transfusion independent and maintained hemoglobin levels equal to or above 8 g/dl.

These '387 anemia response data are stronger and more credible than what was presented last spring because Monday's results are culled from many more patients enrolled at multiple clinical trial sites.

If '387 can reverse the anemia associated with myelofibrosis, it will have a legitimate superiority claim over Incyte's (INCY - Get Report) recently approved myelofibrosis drug Jakafi, which has no effect on anemia.

Based on the positive anemia response data released Monday, the current valuation gap between Incyte ($1.8 billion market cap) and YM Bio ($170 million market cap) is way too big even considering '387 is two or three years behind in clinical development. "It's a drug," said Crespi Monness Hardt analyst (and YM Bio supporter) Avik Roy, referring to '387.

YM Bio shares closed Monday at $1.46 but were up 24% to $1.81 in after-hours trading as the '387 data were released at the American Society of Hematology (ASH) annual meeting.

Myelofibrosisis is a disorder in which abnormal bone marrow stem cells produce scar tissue that replaces healthy marrow. Patients with myelofibrosis suffer from anemia and enlarged spleens. YM Bio's '387 and Incyte's Jakafi belong to a class of oral drugs that block the effects of Janus kinase (JAK) enzymes which play a role in diseases that cause bone marrow cells to grow uncontrollably.

The YM Bio phase I/II study enrolled 166 myelofibrosis patients across six study sites, treating them with 150 mg or 300 mg of '387 daily.

Of the 142 patients evaluable, 31% achieved a spleen response with a median duration of response not yet reached. Forty-nine percent of patients achieved more than a 50% maximal decrease in spleen size from baseline.

Measured by magnetic resonance imaging, the '387 spleen response rate was 64%, which is defined as a 35% drop in spleen volume.

Twenty percent of patients experienced mild peripheral neuropathy, while 33% of patients reported thrombocytopenia, or low platelet counts, with 6% grade 4. Twelve patients, or 7%, died during the core portion of the study.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
INCY $74.36 2.89%
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs